Heidi and Tandem are pursuing broader roles in clinical work, but their funding announcements do not establish an overall winner. As described in September 2026, Heidi emphasises supervised activity around care, while Tandem sets out an ambition for an AI-native clinic operating system. The useful comparison is how each ambition becomes dependable, locally available work, not whose announcement contains the largest total.
This comparison is published by iatroX and includes iatroX as a separate reference and learning option. We are not presenting ourselves as an independent reviewer or as a substitute for either company's documentation platform.
Compare the financing categories first
Heidi's announcement on 22 September 2026 describes a US$100 million Series C led by Blackbird, plus US$240 million growth investment led by General Catalyst's Customer Value Fund. Tandem's announcement on 14 September 2026 describes a US$100 million Series B led by the Scaleup Europe Fund, managed by EQT. Those equity rounds belong in the same comparison category; Heidi's additional growth financing belongs in another. Heidi and Tandem provide the respective figures.
Heidi reported a US$900 million valuation in its September 2026 announcement; Tandem did not state one in the announcement reviewed. That missing number should remain missing. Nor does a Series C label automatically imply that a product is more mature for a particular specialty than one backed by a Series B. Funding stage describes a financing history, not a clinical capability test.
The practical inference is that both companies have fresh resources to pursue expansion. How effectively those resources are used remains a question about execution, retention and evidence.
Two descriptions of a wider platform
Heidi's September 2026 direction extends beyond notes towards supervised work associated with the consultation. Its accompanying announcement also states that the forthcoming capabilities it describes will not be available in the UK and EU. That qualification does not apply automatically to existing products. Heidi's release should therefore be read as both an ambition and a statement of scope.
Tandem's 14 September 2026 announcement describes moving from a medical assistant towards broader clinic operations, including patient flow, scheduling, triage and communications. Its existing product context includes documentation, referrals, coding and clinical decision support. A roadmap towards broader operations is not evidence that every element of the proposed clinic operating system is already deployed. Tandem's announcement makes the current-to-future transition explicit.
These descriptions overlap, but they are not identical specifications. Before comparing features, translate each into an activity with an input, an approval point, an output and a destination. That creates something a clinician or operational leader can evaluate.
Distribution is not a simple individual-versus-institution split
It would be misleading to label Heidi an individual-user product and Tandem an institutional product as though either company had only one route to adoption. The relevant issue is how a particular user gets access and what comes with that route.
An individual account can make evaluation easier, but does not settle organisational approval or integration. An institutionally procured service may come with configuration and support, but its included functionality still depends on the agreement. A partner-delivered product can sit inside familiar software without exposing every capability available elsewhere in the supplier's portfolio.
Accurx's partnership announcement, published on 27 May 2025 and checked on 22 September 2026, says Accurx Scribe is built on Tandem's technology. This establishes a delivery relationship, not identity between Accurx Scribe and every present or future Tandem product. Accurx's explanation is essential context for UK comparisons.
A fictional multi-site clinic comparison
Imagine a clinic group reviewing tools for two different problems. Its outpatient teams want fewer steps between a consultation and a reviewed referral. Its operations team wants clearer responsibility for follow-up messages that have not been completed.
The group should not combine these into a single score labelled "AI platform". The first assessment can test note quality, referral drafting and record transfer. The second needs evidence about work queues, ownership, outstanding tasks and recovery from failed communication. A supplier could perform well on one and not yet provide the other.
The group also specifies who performs review. A function that saves time for the consulting clinician but creates repeated reconciliation work for administrative staff may still be useful, but the trade-off must be visible. The evaluation should follow the whole task through the team, not stop when the clinician closes a window.
No comparative product run was performed for this article. These scenarios define a practical assessment, with results to be published only after an actual authorised run.
A common scorecard without invented rankings
The first category should be useful functionality available in the buyer's market and purchasing route. The next should describe integration depth: reading relevant context, preparing an output, transferring it and confirming what was saved are separate capabilities.
Reliability should be assessed through task completion, corrections and unresolved exceptions. Review burden belongs beside time saved, rather than beneath it in small print. Customer retention can inform commercial durability where comparable data are published, but it cannot stand in for clinical benefit.
Do not build an adoption league table from countries reached, organisations served and consultations processed. They answer different questions. A count of organisations may not describe active individual use; a volume of consultations does not reveal how many outputs required correction. Without matched definitions and periods, comparison by category is more honest than numerical ranking.
Learning remains a different job
Per iatroX product information, September 2026, Ask-iatroX is free clinical reference, while the paid learning subscription includes adaptive question banks, spaced repetition, Socratic Tutor, a study planner, simulations and CPD tools. These functions support revision and professional learning rather than saving documentation into a clinical record. The question-bank entry point and Socratic Tutor describe the learning context.
For example, a trainee might finish a well-documented clinic yet recognise a recurring weakness in explaining why a management option is appropriate. A reference answer can inform the question; an attempted quiz and targeted follow-up can turn it into a learning task. That is complementary to the workflow purchase, not a reason to classify iatroX as another clinic operating system.
Verdict by reader scenario
For a buyer already working effectively within an Accurx deployment, the sensible starting point is the functionality available through that route, not an assumption that a new platform is required. For an organisation considering Heidi's broader proposition, the starting point is a market-specific demonstration and confirmation of which announced capabilities are actually obtainable.
For a clinic seeking end-to-end operational change, neither funding headline is enough: require an implementation plan for the named work. For a clinician whose main problem is revision or continued learning, iatroX belongs in a separate learning-tool comparison. The preferred approach depends on the job, not an overall company winner.
Frequently asked questions
Is Heidi's financing directly comparable with Tandem's?
The US$100 million equity rounds announced in September 2026 can be compared as financing categories. Heidi's separate US$240 million growth investment should not be treated as part of its equity round when making that comparison.
Is Accurx Scribe the same as the entire Tandem platform?
No: Accurx describes Scribe as built on Tandem technology. A partnership does not establish that every Tandem function is included in each Accurx deployment.
Which platform should a clinician choose?
Choose by the specific work, local availability, integration and review requirements. A separate learning tool may still be useful whichever documentation platform is deployed.